Investors Heavily Search Novavax, Inc. ( NVAX ) : Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )
Only 5.6% of children aged 6 months to 4 years old are vaccinated against COVID-19, CDC says. The FDA may not renew Pfizer's pediatric COVID-19 vaccine authorization for the 2025 season. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Novavax ( NVAX ) Profit Jumps on Milestone
Novavax ( NASDAQ:NVAX ) , known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment ...
Why Is Novavax Stock Soaring Wednesday? - Novavax ( NASDAQ:NVAX )
Q2 sales of $239 million beat the consensus of $156.29 million; EPS of $0.62 vs est. loss of $0.05. FY25 guidance raised to $1 billion-$1.05 billion from $975 million-$1.025 billion; Wall Street est. was $1.039 billion. The market's back, and these 3 income stocks are thriving. See them here→
Novavax ( NVAX ) Q2 Earnings and Revenues Top Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Novavax ( NVAX ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
Here is What to Know Beyond Why Novavax, Inc. ( NVAX ) is a Trending Stock
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax ( NVAX ) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates - Novavax ( NASDAQ:NVAX )
Novavax's H5N1 vaccine showed a protective antibody response after just one dose in primates. Two-dose regimens boosted immunity, with data suggesting potential protection against future virus variants. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin ...
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novavax ( NVAX ) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.
Is Trending Stock Novavax, Inc. ( NVAX ) a Buy Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have ...
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Moderna ( NASDAQ:MRNA )
The FDA fully approves Moderna's Spikevax for children six months to 11 years at high risk of COVID-19. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On The U.S.
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA )
17 CDC vaccine advisers were dismissed and replaced with anti-vaccine voices, lawsuit claims. Groups seek injunction to reverse COVID-19 vaccine rollback for kids, pregnant women. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any ...
Novavax ( NVAX ) Dips More Than Broader Market: What You Should Know
Novavax (NVAX) closed at $6.61 in the latest trading session, marking a -2.79% move from the prior day.
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )
FDA chief Prasad overruled staff to limit COVID shots to seniors, high-risk groups. Moderna must study myocarditis risk further to keep approval for its updated vaccine. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 ...
Is Most-Watched Stock Novavax, Inc. ( NVAX ) Worth Betting on Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ginkgo Bioworks ( DNA ) Soars 18.9%: Is Further Upside Left in the Stock?
Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
The phase three study data clears the path forward for Moderna's combination jab targeting Covid-19 and influenza.
Novavax ( NVAX ) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Is Cidara Therapeutics Stock Trading Higher On Monday? - Cidara Therapeutics ( NASDAQ:CDTX )
CD388 showed 76.1% flu prevention efficacy at highest dose over 24 weeks. NAVIGATE trial met all primary and secondary endpoints with no safety issues. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. Cidara Therapeutics, Inc.
Novavax ( NVAX ) Ascends While Market Falls: Some Facts to Note
Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.
Novavax, Inc. ( NVAX ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Artivion ( NYSE:AORT ) , Coinbase Global ( NASDAQ:COIN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst William Plovanic initiated coverage on Artivion, Inc.
Why Is Fate Therapeutics ( FATE ) Up 61.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Novavax ( NASDAQ:NVAX )
Novavax's combo and standalone flu shots triggered a 2.4-5.7x rise in immune response over baseline in seniors. Over 98% of adverse events were mild or moderate in Novavax's Phase 3 trial of 2,000 adults aged 65+. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre ...
Novavax, Inc. ( NVAX ) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Moderna ( NASDAQ:MRNA )
mNexspike showed 9.3% higher efficacy vs. Spikevax and 13.5% higher efficacy in adults 65 and older. The Phase 3 trial enrolled 11,400 participants and showed a similar safety profile to Moderna's original COVID vaccine. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Novavax ( NASDAQ:NVAX )
The U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced that the Centers for Disease Control and Prevention will no longer recommend COVID-19 vaccines for healthy children and pregnant women, sparking criticism from public health experts who cite ongoing risks.
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort - CureVac ( NASDAQ:CVAC ) , Moderna ( NASDAQ:MRNA )
The President Donald Trump administration terminated a nearly $600 million contract to Moderna Inc. MRNA for developing an mRNA-based bird flu vaccine, ending a key former President Joe Biden-era pandemic preparedness initiative.
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children - Moderna ( NASDAQ:MRNA )
CDC's online immunization schedule still listed the COVID-19 vaccine as of Tuesday. Kennedy was joined by FDA's Makary and NIH's Bhattacharya in the announcement. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas-now 60% off for Memorial Day. The U.S.
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
Novavax, Inc. ( NVAX ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
What's Driving the Market Sentiment Around Novavax? - Novavax ( NASDAQ:NVAX )
Novavax's NVAX short percent of float has fallen 17.46% since its last report. The company recently reported that it has 42.33 million shares sold short, which is 26.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.4 days to cover ...
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
What's Going On With Vaccine Stocks Today? - BioNTech ( NASDAQ:BNTX )
Vaccine stocks are rising after the FDA announced it will consider updating COVID-19 vaccines to target the rapidly spreading LP.8.1. The FDA will require new clinical trials for annual boosters in healthy people under 65, limiting this fall's shots.
